Elevance Health, Inc.
ELVAPI behind this page
ELV Q3 2025 request
Playground key active
/api/financials?ticker=ELV&year=2025&quarter=3
Pick an endpoint and run the request.Income Statement
| Metric | Q3 2025 | Q3 2024 | YoY |
|---|---|---|---|
| Premiums Earned Net | 41,791 | 36,809 | +13.5% |
Show Business Segments breakouts |
|||
| Carelon Services · Operating Segments | 1,762 | 680 | +159.1% |
| Health Benefits · Operating Segments | 40,304 | 36,448 | +10.6% |
| Total Carelon · Operating Segments | 1,762 | 680 | +159.1% |
Show Consolidation Items breakouts |
|||
| Intersegment Elimination | -275 | -319 | +13.8% |
| Revenue (Q) | — | — | — |
Show Product Lines breakouts |
|||
| Product | 6,159 | 5,887 | +4.6% |
| Product · CarelonRx | 6,159 | 5,887 | +4.6% |
| Product · Total Carelon | 6,159 | 5,887 | +4.6% |
| Service fees | 2,137 | 2,023 | +5.6% |
| Service fees · Carelon Services | 191 | 201 | -5.0% |
| Service fees · CarelonRx | 4 | 2 | +100.0% |
| Service fees · Health Benefits | 1,942 | 1,830 | +6.1% |
| Service fees · Total Carelon | 195 | 203 | -3.9% |
| Operating Revenue | 50,087 | 44,719 | +12.0% |
Show Business Segments breakouts |
|||
| Carelon Services · Operating Segments | 5,371 | 3,757 | +43.0% |
| Carelon Services · Operating Segments | 1,953 | 881 | +121.7% |
| Carelon Services · Operating Segments | 7,324 | 4,638 | +57.9% |
| CarelonRx · Operating Segments | 4,834 | 3,254 | +48.6% |
| CarelonRx · Operating Segments | 6,163 | 5,889 | +4.7% |
| CarelonRx · Operating Segments | 10,997 | 9,143 | +20.3% |
| Corporate And Other · Operating Segments | 149 | 84 | +77.4% |
| Corporate And Other · Operating Segments | 149 | 74 | +101.4% |
| Health Benefits · Operating Segments | 42,246 | 38,278 | +10.4% |
| Health Benefits · Operating Segments | 42,246 | 38,278 | +10.4% |
| Reportable Segments | 50,087 | 44,719 | +12.0% |
| Total Carelon · Operating Segments | 10,205 | 7,011 | +45.6% |
| Total Carelon · Operating Segments | 8,116 | 6,770 | +19.9% |
| Total Carelon · Operating Segments | 18,321 | 13,781 | +32.9% |
Show Consolidation Items breakouts |
|||
| Intersegment Elimination | -10,629 | -7,414 | -43.4% |
| Intersegment Elimination · Operating revenue - affiliated | -10,354 | -7,095 | -45.9% |
| Intersegment Elimination · Operating revenue - unaffiliated | -275 | -319 | +13.8% |
Show Major Customers breakouts |
|||
| Operating revenue - unaffiliated | 50,087 | 44,719 | +12.0% |
| Net Investment Income | 625 | 551 | +13.4% |
Show Business Segments breakouts |
|||
| Reportable Segments | 625 | 551 | +13.4% |
| Net Losses Gains On Financial Instruments | -1 | -125 | +99.2% |
Show Business Segments breakouts |
|||
| Reportable Segments | -1 | -125 | +99.2% |
| Revenue | 50,711 | 45,106 | +12.4% |
Show Business Segments breakouts |
|||
| Reportable Segments | 50,711 | 45,106 | +12.4% |
| Policyholder Benefits And Claims Incurred Net | 38,140 | 32,949 | +15.8% |
Show Business Segments breakouts |
|||
| Carelon Services · Operating Segments | 6,349 | 3,767 | +68.5% |
| Corporate And Other · Operating Segments | 4 | 5 | -20.0% |
| Health Benefits · Operating Segments | 36,845 | 32,724 | +12.6% |
| Total Carelon · Operating Segments | 6,349 | 3,767 | +68.5% |
Show Legal Entity breakouts |
|||
| Mosaic Health · Equity Method Investee | 162 | — | — |
Show Consolidation Items breakouts |
|||
| Intersegment Elimination | -5,058 | -3,547 | -42.6% |
Show Schedule Of Equity Method Investment Equity Method Investee Name breakouts |
|||
| Liberty Dental | 149 | — | — |
| Cost of Revenue | 5,380 | 5,093 | +5.6% |
Show Business Segments breakouts |
|||
| CarelonRx · Operating Segments | 10,209 | 8,336 | +22.5% |
| Total Carelon · Operating Segments | 10,209 | 8,336 | +22.5% |
Show Consolidation Items breakouts |
|||
| Intersegment Elimination | -4,829 | -3,243 | -48.9% |
| Selling, General & Administrative | 5,272 | 5,269 | +0.1% |
Show Business Segments breakouts |
|||
| Carelon Services · Operating Segments | 756 | 687 | +10.0% |
| CarelonRx · Operating Segments | 232 | 188 | +23.4% |
| Corporate And Other · Operating Segments | 226 | 1,068 | -78.8% |
| Health Benefits · Operating Segments | 4,800 | 3,950 | +21.5% |
| Total Carelon · Operating Segments | 988 | 875 | +12.9% |
Show Consolidation Items breakouts |
|||
| Intersegment Elimination | -742 | -624 | -18.9% |
| Interest Expense | 351 | 300 | +17.0% |
Show Business Segments breakouts |
|||
| Reportable Segments | 351 | 300 | +17.0% |
| Amortization Of Intangible Assets | 162 | 122 | +32.8% |
Show Business Segments breakouts |
|||
| Reportable Segments | 162 | 122 | +32.8% |
| Benefits Losses And Expenses | 49,305 | 43,733 | +12.7% |
| Income Before Taxes | 1,406 | 1,373 | +2.4% |
Show Business Segments breakouts |
|||
| Reportable Segments | 1,406 | 1,373 | +2.4% |
| Income Tax Expense (Benefit) | 219 | 365 | -40.0% |
| Net Income | 1,187 | 1,008 | +17.8% |
Show Equity Components breakouts |
|||
| Noncontrolling Interest | -2 | -8 | +75.0% |
| Retained Earnings | 1,189 | 1,016 | +17.0% |
| Net Income Loss Attributable To Noncontrolling Interest | 2 | 8 | -75.0% |
| Net Income | 1,189 | 1,016 | +17.0% |
| EPS (Basic) | 5.32 | 4.38 | +21.5% |
| EPS (Diluted) | 5.32 | 4.36 | +22.0% |
| Common Stock Dividends Per Share Declared | 1.71 | 1.63 | +4.9% |
| Operating Income | 1,295 | 1,408 | -8.0% |
Show Business Segments breakouts |
|||
| Carelon Services · Operating Segments | 219 | 184 | +19.0% |
| CarelonRx · Operating Segments | 556 | 619 | -10.2% |
| Corporate And Other · Operating Segments | -81 | -999 | +91.9% |
| Health Benefits · Operating Segments | 601 | 1,604 | -62.5% |
| Reportable Segments | 1,295 | 1,408 | -8.0% |
| Total Carelon · Operating Segments | 775 | 803 | -3.5% |
| Comprehensive Income | 1,406 | 1,914 | -26.5% |
| Wtd Avg Shares (Basic) | 223.3 | 231.9 | -3.7% |
| Wtd Avg Shares (Diluted) | 223.7 | 233.1 | -4.0% |
Balance Sheet
| Metric | Q3 2025 | Q3 2024 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 8,713 | 7,866 | +10.8% |
| Available For Sale Securities Debt Securities Current | 26,283 | 28,954 | -9.2% |
| Equity Securities Fv Ni | 1,220 | 1,113 | +9.6% |
Show Financial Instrument breakouts |
|||
| Common equity securities | 31 | 40 | -22.5% |
| Exchange Traded Funds | 1,129 | 994 | +13.6% |
| Private Equity Funds | 60 | 79 | -24.1% |
| Premiums Receivable At Carrying Value | 9,535 | 7,209 | +32.3% |
| Self Funded Receivables Net | 5,122 | 5,135 | -0.3% |
| Other Receivables | 7,692 | 6,055 | +27.0% |
| Other Assets Current | 5,213 | 5,949 | -12.4% |
| Total Current Assets | 63,778 | 62,846 | +1.5% |
| Non-Current Assets | |||
| Property, Plant & Equipment | 4,657 | 4,505 | +3.4% |
| Goodwill | 28,451 | — | — |
Show Business Acquisition breakouts |
|||
| Centers Plan for Healthy Living LLC | 246 | — | — |
| RSV QOZB LTSS, Inc | 1,811 | — | — |
| Other Non-Current Assets | 2,777 | — | — |
| Total Assets | 122,749 | 116,533 | +5.3% |
| Other Assets | |||
| Other Long Term Investments | 10,648 | — | — |
Show Fair Value Hierarchy breakouts |
|||
| Fair Value Inputs Level1 · Common equity securities | 7 | — | — |
| Fair Value Inputs Level3 · Estimate Of Fair Value Fair Value Disclosure | 660 | — | — |
Show Financial Instrument breakouts |
|||
| Common equity securities | 7 | — | — |
Show Legal Entity breakouts |
|||
| Mosaic Health · Line Of Credit | 188 | — | — |
Show Schedule Of Equity Method Investment Equity Method Investee Name breakouts |
|||
| Liberty Dental | 127 | — | — |
Show Fair Value By Measurement Basis breakouts |
|||
| Carrying Reported Amount Fair Value Disclosure · Fair Value Measurements Nonrecurring | 678 | — | — |
| Estimate Of Fair Value Fair Value Disclosure · Fair Value Measurements Recurring | 660 | — | — |
| Intangible Assets Net Excluding Goodwill | 11,327 | 10,325 | +9.7% |
| Current Liabilities | |||
| Liability For Claims And Claims Adjustment Expense | 17,148 | 15,346 | +11.7% |
| Other Policyholder Funds | 2,447 | 4,402 | -44.4% |
| Unearned Premiums | 1,831 | 1,793 | +2.1% |
| Accounts Payable And Accrued Liabilities Current | 6,085 | 6,255 | -2.7% |
| Short Term Borrowings | 180 | 360 | -50.0% |
Show Fair Value Hierarchy breakouts |
|||
| Fair Value Inputs Level2 · Estimate Of Fair Value Fair Value Disclosure | 180 | 360 | -50.0% |
Show Fair Value By Measurement Basis breakouts |
|||
| Carrying Reported Amount Fair Value Disclosure · Fair Value Measurements Nonrecurring | 180 | 360 | -50.0% |
| Estimate Of Fair Value Fair Value Disclosure · Fair Value Measurements Recurring | 180 | 360 | -50.0% |
| Current Portion of Long-Term Debt | 749 | 2,100 | -64.3% |
| Other Liabilities Current | 12,438 | 11,614 | +7.1% |
| Total Current Liabilities | 40,878 | 42,033 | -2.7% |
| Non-Current Liabilities | |||
| Available For Sale Securities Debt Securities Noncurrent | 1,111 | 893 | +24.4% |
| Long-Term Debt | 31,173 | 24,688 | +26.3% |
| Deferred Tax Liabilities | 2,315 | 2,092 | +10.7% |
| Other Non-Current Liabilities | 4,137 | 3,593 | +15.1% |
| Total Liabilities | 78,667 | 72,654 | +8.3% |
| Long-Term Debt (Q) | — | — | — |
Show Debt Instrument breakouts |
|||
| Senior Unsecured Notes · Senior Notes | 31,897 | 26,763 | +19.2% |
| Surplus Notes | 25 | 25 | 0.0% |
| Other Liabilities | |||
| Liability For Future Policy Benefits | 164 | 248 | -33.9% |
| Preferred Stock Shares Authorized | 100,000,000 | — | — |
| Stockholders' Equity | |||
| Common Stock | 2 | 2 | 0.0% |
| Additional Paid-In Capital | 8,908 | 9,105 | -2.2% |
| Retained Earnings | 35,586 | 35,157 | +1.2% |
| Accumulated Other Comprehensive Income | -543 | -489 | -11.0% |
| Total Stockholders' Equity | 43,953 | 43,775 | +0.4% |
| Minority Interest | 129 | 104 | +24.0% |
| Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 44,082 | 43,879 | +0.5% |
Show Equity Components breakouts |
|||
| Accumulated Defined Benefit Plans Adjustment Including Portion Attributable To Noncontrolling Interest | -398 | -448 | +11.2% |
| Accumulated Foreign Currency Adjustment Including Portion Attributable To Noncontrolling Interest | -23 | -16 | -43.8% |
| Accumulated Gain Loss Cash Flow Hedge Including Noncontrolling Interest | -202 | -203 | +0.5% |
| Accumulated Net Investment Gain Loss Including Portion Attributable To Noncontrolling Interest | 76 | 173 | -56.1% |
| Accumulated Other Comprehensive Income | -543 | -489 | -11.0% |
| Additional Paid In Capital | 8,908 | 9,105 | -2.2% |
| Aoci Including Portion Attributable To Noncontrolling Interest | -543 | -489 | -11.0% |
| Common Stock | 2 | 2 | 0.0% |
| Future policy benefits: | 7 | 8 | -12.5% |
| Non-credit components of impairments on investments: | -3 | -3 | 0.0% |
| Noncontrolling Interest | 129 | 104 | +24.0% |
| Retained Earnings | 35,586 | 35,157 | +1.2% |
| Total Liabilities & Equity | 122,749 | 116,533 | +5.3% |
Cash Flow Statement
| Metric | YTD Q3 2025 | YTD Q3 2024 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Income Loss From Equity Method Investments | -251 | 15 | -1773.3% |
| Depreciation Amortization And Accretion Net | 1,140 | 995 | +14.6% |
| Deferred Income Taxes | 43 | -258 | +116.7% |
| Asset Impairment Charges | 70 | 103 | -32.0% |
| Stock-Based Compensation | 246 | 220 | +11.8% |
| Increase Decrease In Receivables | -3,282 | -490 | -569.8% |
| Increase Decrease In Trading Securities | -70 | -73 | +4.1% |
| Increase Decrease In Other Operating Assets | -403 | -934 | +56.9% |
| Increase Decrease In Insurance Liabilities | -873 | -1,812 | +51.8% |
| Increase Decrease In Deferred Revenue | 323 | 392 | -17.6% |
| Increase Decrease In Accounts Payable And Other Operating Liabilities | 1,539 | 928 | +65.8% |
| Increase Decrease In Income Taxes Payable Net Of Income Taxes Receivable | -13 | 231 | -105.6% |
| Increase Decrease In Other Operating Capital Net | 26 | 57 | -54.4% |
| Net Cash from Operations | 4,206 | 5,102 | -17.6% |
| Investing Activities | |||
| Payments To Acquire Investments | -12,265 | -14,706 | +16.6% |
| Proceedsfromsaleofequityandfixedmaturitysecurities | 10,658 | 11,611 | -8.2% |
| Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities | 1,195 | 1,481 | -19.3% |
| Increase Decrease In Collateral Held Under Securities Lending | -576 | -160 | -260.0% |
| Payments To Acquire Businesses Net Of Cash Acquired | 55 | -1,124 | +104.9% |
| Capital Expenditures | -823 | -934 | +11.9% |
| Other Investing Activities | -52 | -96 | +45.8% |
| Net Cash from Investing | -1,808 | -3,529 | +48.8% |
| Financing Activities | |||
| Proceeds From Issuance Of Long Term Debt | 2,994 | 2,580 | +16.0% |
| Repayments Of Long Term Debt | -2,150 | -800 | -168.8% |
| Proceeds From Short Term Debt | 990 | 210 | +371.4% |
| Repayments Of Short Term Debt | -1,175 | -75 | -1466.7% |
| Increase Decrease In Securities Lending Payable | 576 | 158 | +264.6% |
| Increase Decrease In Outstanding Checks Financing Activities | 77 | -172 | +144.8% |
| Share Repurchases | -2,134 | -1,089 | -96.0% |
| Payments Of Dividends | -1,152 | -1,135 | -1.5% |
| Proceeds From Stock Options Exercised | 21 | 205 | -89.8% |
| Tax Withholding for Share Compensation | -31 | -106 | +70.8% |
| Proceeds From Payments For Other Financing Activities | 10 | 9 | +11.1% |
| Net Cash from Financing | -1,974 | -215 | -818.1% |
| Other Cash Flow | |||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 1 | 2 | -50.0% |
| Net Change in Cash | 425 | 1,360 | -68.8% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 8,713 | 7,866 | +10.8% |
Values in millions USD. Source: SEC EDGAR 10-Q filing.